Marksans Pharma Q1 Results
- BSE: 524404
- NSE: MARKSANS
- ISIN: INE750C01026
- Sector: Biotechnology & Drugs
BSE
330.30
-0.15 (-0.05%)
-0.15 (-0.05%)Volume1.18 L
Updated: Thu 10 Sep, 2026 | 15:29:40
NSE
330.40
0.25 (0.08%)
0.25 (0.08%)Volume1.30 M
Updated: Thu 10 Sep, 2026 | 15:31:53
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q1 Results Highlights
- Total Income₹840.80 Cr.(35.61%)
- Operating Profit₹188.17 Cr.(144.31%)
- Profit After Tax₹157.17 Cr.(169.50%)
- Operating Margin22.38%(80.15%)
Note: Comparison is on YoY basis
Quarterly - Marksans Pharma Q1 Results
*All figures in crores except per share values
| Fiscal Period | Jun 26 | Mar 26 | QoQ Comp | Jun 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 652.63 | 684.98 | -4.72% | 482.63 | 20.20% |
| Depreciation/ Amortization | 24.86 | 24.29 | 2.37% | 20.44 | 7.63% |
| Operating Income | 188.17 | 171.13 | 9.96% | 107.99 | 144.31% |
| Net Income | 157.17 | 148.13 | 6.10% | 88.75 | 169.50% |
| Other Operating Expenses Total | 170.00 | 163.28 | 4.11% | 119.92 | 6.47% |
| Net Income Before Taxes | 206.57 | 200.00 | 3.29% | 120.02 | 169.68% |
| Total Revenue | 840.80 | 856.11 | -1.79% | 590.62 | 35.61% |
| Selling/ General/ Admin Expenses Total | 114.29 | 106.76 | 7.06% | 80.48 | 16.17% |
| Diluted Normalized EPS | 3.47 | 3.27 | 6.18% | 1.96 | 168.99% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.